Partner With Us NRI

Company details

6M Return -21.53%
1Y Return 9.79%
Mkt Cap.(Cr) 808.76
Volume 822
Div Yield 1.96%
OI Chg %
Volume 822

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 216.45 Cr FV: 8.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,081.38 -37,247.74
LAST 3M 71,111.08 -54,074.79
LAST 6M 141,746.37 -188,969.09
LAST 12M 212,995.89 -183,256.64
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Aug 13, 2021 Dividend 90
Mar 24, 2020 Dividend 50


  • About Company
  • Company Info
  • Listing Info
  • RPG Life Sciences Ltd is engaged in the development, manufacture, and marketing of bulk drugs and formulations primarily in India. The company provides active pharmaceutical ingredients and generic formulations, as well as medications for critical and chronic ailments. They also manufacture life saving drugs using biotechnology. The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.

Read More

Registered Address

RPG House, 463 Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24981650
Email : info:rpglifesciences.com
Website : http://www.rpglifesciences.com


Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 8
Market Lot Equity Shares : 1
BSE Code : 532983
Book Closure Date (Month) :
BSE Group : B
ISIN : INE105J01010

ICICIdirect RPG Life Sciences Ltd FAQ

You can buy RPG Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy RPG Life Sciences Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 27, 2022 04:01 PM the closing price of RPG Life Sciences Ltd was ₹ 489.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 27, 2022 04:01 PM, the market cap of RPG Life Sciences Ltd stood at ₹ 808.76.
The latest PE ratio of RPG Life Sciences Ltd as of May 27, 2022 04:01 PM is 15.74
The latest PB ratio of RPG Life Sciences Ltd as of May 27, 2022 04:01 PM is 0.32
The 52-week high of RPG Life Sciences Ltd is ₹ 751.80 while the 52-week low is ₹ 425.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote